The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Hepatocellular carcinoma: Diagnosis and treatment
Open accessAbstract
Hepatocellular carcinoma is the most frequent primary malignancy of the liver and appears to be rising in incidence in the United States and other developed western countries. Imaging studies play a key role in diagnosis of hepatocellular carcinoma, and more and more commonly, patients are being diagnosed at an asymptomatic stage. The use of triphasic computed tomography scanning and improved magnetic resonance imaging equipment and protocols has led to greater sensitivity and specificity for these techniques in diagnosis of hepatocellular carcinoma. Accurate staging of hepatocellular carcinoma is important in determining prognosis and in helping decide the best treatment for each patient. No one staging system appears optimal, but important factors to be considered are the size of the tumor, severity of underlying liver disease, and the functional status of the patient. Liver transplantation has grown in importance as a treatment for hepatocellular carcinoma but may be limited by availability of donor organs and long waiting times. This situation may be improved by greater use of living donor liver transplantation. Hepatic resection remains an important treatment modality for hepatocellular carcinoma, particularly in the absence of cirrhosis. Tumor ablation by alcohol injection or radiofrequency ablation is associated with favorable outcomes and may be considered a potentially curative treatment. Early diagnosis of hepatocellular carcinoma remains a key goal in improving the poor prognosis of this form of liver cancer. Identifying hepatocellular carcinoma at an early stage is often associated with having better treatment options for patients with small, asymptomatic tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Yao, F. Y., Ferrell, L., Bass, N. M., Watson, J. J., Bacchetti, P., Venook, A., Ascher, N. L., & Roberts, J. P. (2001) · Hepatology · doi:10.1053/jhep.2001.24563 · Cited by 2,262
Okuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., Nakajima, Y., & Ohnishi, K. (1985) · Cancer · doi:10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e · Cited by 1,931
Llovet, J. M., Fuster, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510300629 · Cited by 1,708
Small Hepatocellular Carcinoma: Treatment with Radio-frequency Ablation versus Ethanol Injection
Livraghi, T., Goldberg, S. N., Lazzaroni, S., Meloni, F., Solbiati, L., & Gazelle, G. S. (1999) · Radiology · doi:10.1148/radiology.210.3.r99fe40655 · Cited by 1,283
A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients
(1998) · Hepatology · doi:10.1002/hep.510280322 · Cited by 1,238
Llovet, J. M., Bustamante, J., Castells, A., Vilana, R., Del Carmen Ayuso, M., Sala, M., Brú, C., Rodés, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510290145 · Cited by 1,190
Cited by
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Hu, B., Yang, X.-R., Xu, Y., Sun, Y.-F., Sun, C., Guo, W., Zhang, X., Wang, W.-M., Qiu, S.-J., Zhou, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0442 · Cited by 2,493
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
AASLD practice guidelines: Evaluation of the patient for liver transplantation†
Murray, K. F., & Carithers, R. L. (2005) · Hepatology · doi:10.1002/hep.20704 · Cited by 939
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
Capurro, M., Wanless, I. R., Sherman, M., Deboer, G., Shi, W., Miyoshi, E., & Filmus, J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00689-9 · Cited by 917
Resection and Liver Transplantation for Hepatocellular Carcinoma
Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871198 · Cited by 879
The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma
Llovet, J. M., Fuster, J., & Bruix, J. (2004) · Liver Transplantation · doi:10.1002/lt.20034 · Cited by 700
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma
Marrero, J. A., Fontana, R. J., Fu, S., Conjeevaram, H. S., Su, G. L., & Lok, A. S. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.10.005 · Cited by 511
Updated treatment approach to hepatocellular carcinoma
Llovet, J. M. (2005) · Journal of Gastroenterology · doi:10.1007/s00535-005-1566-3 · Cited by 508
Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt Signaling
Capurro, M. I., Xiang, Y.-Y., Lobe, C., & Filmus, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4244 · Cited by 469
Zhong, J.-H., Ke, Y., Gong, W.-F., Xiang, B.-D., Ma, L., Ye, X.-P., Peng, T., Xie, G.-S., & Li, L.-Q. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000236 · Cited by 464
Glypican-3 as a Serum Marker for Hepatocellular Carcinoma
Capurro, M., & Filmus, J. (2005) · Cancer Research · doi:10.1158/0008-5472.372.65.1 · Cited by 432
Prospective validation of the Barcelona Clinic Liver Cancer staging system
Cillo, U., Vitale, A., Grigoletto, F., Farinati, F., Brolese, A., Zanus, G., Neri, D., Boccagni, P., Srsen, N., D'Amico, F., et al. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.12.015 · Cited by 425
Adam, R., Azoulay, D., Castaing, D., Eshkenazy, R., Pascal, G., Hashizume, K., Samuel, D., & Bismuth, H. (2003) · Annals of Surgery · doi:10.1097/01.sla.0000090449.87109.44 · Cited by 377
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma
Marrero, J. A., Romano, P. R., Nikolaeva, O., Steel, L., Mehta, A., Fimmel, C. J., Comunale, M. A., D'Amelio, A., Lok, A. S., & Block, T. M. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.05.028 · Cited by 364
Liver fibrosis: from the bench to clinical targets
Pinzani, M., & Rombouts, K. (2004) · Digestive and Liver Disease · doi:10.1016/j.dld.2004.01.003 · Cited by 336
Diagnosis of hepatocellular carcinoma
Bialecki, E. S., & Di Bisceglie, A. M. (2005) · HPB · doi:10.1080/13651820410024049 · Cited by 334
Self-citationColnot, S., Decaens, T., Niwa-Kawakita, M., Godard, C., Hamard, G., Kahn, A., Giovannini, M., & Perret, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404761101 · Cited by 328
Hippo, Y., Watanabe, K., Watanabe, A., Midorikawa, Y., Yamamoto, S., Ihara, S., Tokita, S., Iwanari, H., Ito, Y., Nakano, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2191 · Cited by 297
Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma
Guo, Y., Chen, Y., Ito, H., Watanabe, A., Ge, X., Kodama, T., & Aburatani, H. (2006) · Gene · doi:10.1016/j.gene.2006.07.011 · Cited by 291
Li, T., Xie, J., Shen, C., Cheng, D., Shi, Y., Wu, Z., Deng, X., Chen, H., Shen, B., Peng, C., et al. (2016) · Oncogene · doi:10.1038/onc.2015.223 · Cited by 272
RetractedYao, F. Y., Bass, N. M., Nikolai, B., Merriman, R., Davern, T. J., Kerlan, R., Ascher, N. L., & Roberts, J. P. (2003) · Liver Transplantation · doi:10.1053/jlts.2003.50147 · Cited by 271
Fibrosis in chronic liver diseases: diagnosis and management
Pinzani, M., Rombouts, K., & Colagrande, S. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.12.008 · Cited by 267
Zucman-Rossi, J., Benhamouche, S., Godard, C., Boyault, S., Grimber, G., Balabaud, C., Cunha, A. S., Bioulac-Sage, P., & Perret, C. (2007) · Oncogene · doi:10.1038/sj.onc.1209824 · Cited by 256
Vivarelli, M., Guglielmi, A., Ruzzenente, A., Cucchetti, A., Bellusci, R., Cordiano, C., & Cavallari, A. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000129672.51886.44 · Cited by 256
Metadata
- Authors
- Befeler, A. S., & di Bisceglie, A. M.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2002-05
- Volume
- 122
- Issue
- 6
- Pages
- 1609-1619
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2060893815
- Cited by
- 602
- References
- 39
- FWCI
- 21.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.